Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6107) 6107
Publication (351) 351
Newsletter (109) 109
Book Review (55) 55
Newspaper Article (28) 28
Magazine Article (26) 26
Book Chapter (13) 13
Book / eBook (10) 10
Conference Proceeding (9) 9
Trade Publication Article (3) 3
Transcript (2) 2
Dissertation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4916) 4916
bcg vaccine - therapeutic use (3850) 3850
female (2264) 2264
male (2238) 2238
animals (1494) 1494
immunotherapy (1310) 1310
middle aged (1303) 1303
index medicus (1290) 1290
adult (1179) 1179
bcg (1161) 1161
aged (1156) 1156
bcg vaccine - administration & dosage (1021) 1021
urinary bladder neoplasms - therapy (983) 983
tuberculosis (951) 951
bcg vaccine (915) 915
mice (829) 829
bcg vaccine - adverse effects (786) 786
administration, intravesical (782) 782
immunology (706) 706
urinary bladder neoplasms - drug therapy (683) 683
tuberculosis - prevention & control (665) 665
urology & nephrology (648) 648
adjuvants, immunologic - therapeutic use (638) 638
child (620) 620
urinary bladder neoplasms - pathology (588) 588
vaccination (588) 588
antitubercular agents - therapeutic use (575) 575
adolescent (542) 542
cancer (532) 532
bladder cancer (529) 529
vaccines (484) 484
treatment outcome (464) 464
time factors (445) 445
follow-up studies (424) 424
infant (423) 423
carcinoma, transitional cell - therapy (422) 422
child, preschool (422) 422
bcg vaccine - immunology (420) 420
oncology (416) 416
prognosis (414) 414
combined modality therapy (408) 408
bacillus-calmette-guerin (402) 402
antineoplastic agents - therapeutic use (380) 380
melanoma - therapy (368) 368
aged, 80 and over (366) 366
infectious diseases (365) 365
bcg vaccines (354) 354
care and treatment (354) 354
clinical trials as topic (354) 354
research (353) 353
tuberculin test (339) 339
infection (325) 325
drug therapy, combination (324) 324
therapy (323) 323
research article (321) 321
health aspects (313) 313
neoplasm staging (312) 312
risk factors (303) 303
tuberculosis, pulmonary - prevention & control (297) 297
isoniazid - therapeutic use (291) 291
mycobacterium bovis - immunology (284) 284
infections (283) 283
antigens (279) 279
immunization (278) 278
urinary bladder neoplasms - surgery (275) 275
medicine, research & experimental (274) 274
mycobacterium tuberculosis - immunology (271) 271
recurrence (270) 270
tumors (263) 263
mycobacterium bovis (258) 258
neoplasms - therapy (249) 249
tuberculosis - epidemiology (244) 244
carcinoma, transitional cell - drug therapy (242) 242
tuberculosis - immunology (240) 240
medicine (238) 238
immunity, cellular (236) 236
bacillus calmette-guerin (235) 235
carcinoma in situ - therapy (233) 233
infant, newborn (232) 232
carcinoma (231) 231
carcinoma, transitional cell - pathology (226) 226
mycobacterium-tuberculosis (222) 222
immunity (221) 221
immunotherapy - methods (221) 221
vaccine (221) 221
disease progression (218) 218
microbiology (217) 217
tuberculosis - drug therapy (216) 216
analysis (215) 215
prospective studies (215) 215
retrospective studies (215) 215
urinary bladder neoplasms - immunology (211) 211
risk (208) 208
medicine, general & internal (206) 206
transitional-cell carcinoma (206) 206
tuberculosis - diagnosis (204) 204
neoplasm recurrence, local (203) 203
mice, inbred c57bl (195) 195
medical research (194) 194
neoplasm invasiveness (194) 194
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5206) 5206
French (251) 251
German (224) 224
Japanese (134) 134
Russian (106) 106
Spanish (97) 97
Italian (72) 72
Chinese (41) 41
Polish (40) 40
Portuguese (23) 23
Romanian (18) 18
Czech (17) 17
Dutch (16) 16
Swedish (13) 13
Finnish (8) 8
Hebrew (8) 8
Danish (6) 6
Bulgarian (5) 5
Hungarian (5) 5
Croatian (4) 4
Norwegian (4) 4
Korean (2) 2
Afrikaans (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Stool microbiota and vaccine responses of infants
by Huda, M. Nazmul and Lewis, Zachery and Kalanetra, Karen M and Rashid, Mamunur and Ahmad, Shaikh M and Raqib, Rubhana and Qadri, Firdausi and Underwood, Mark A and Mills, David A and Stephensen, Charles B
Pediatrics, ISSN 0031-4005, 08/2014, Volume 134, Issue 2, pp. e362 - e372
OBJECTIVE: Oral vaccine efficacy is low in less-developed countries, perhaps due to intestinal dysbiosis. This study determined if stool microbiota composition... 
Proteobacteria | Bifidobacterium | Antibody | Polio | Vaccine | Intestinal | Hepatitis | Bangladesh | Microbiota | Tuberculosis | Actinobacteria | T lymphocyte | Tetanus | microbiota | SYSTEM | antibody | PROBIOTIC BACTERIA | INTESTINAL MICROBIOTA | tuberculosis | COLONIZATION | GUT MICROBIOTA | hepatitis | MATURATION | polio | intestinal | vaccine | tetanus | EVOLUTION | IMMUNE-RESPONSES | DISEASE | PEDIATRICS | DIVERSITY | Poliovirus Vaccine, Oral - immunology | Humans | Infant | Male | Vaccines - therapeutic use | Bifidobacterium - isolation & purification | Dysbiosis - immunology | Feces - microbiology | Enterobacteriaceae - immunology | Female | Actinobacteria - isolation & purification | Nutritional Status | Pseudomonas - immunology | RNA, Ribosomal, 16S | DNA, Bacterial - isolation & purification | Microbiota - immunology | Tetanus Toxoid - therapeutic use | Vaccines - immunology | Sequence Analysis, DNA | Hepatitis B Vaccines - therapeutic use | BCG Vaccine - immunology | T-Lymphocytes - immunology | Thymus Gland - immunology | Hepatitis B Vaccines - immunology | Microbiological Techniques | BCG Vaccine - therapeutic use | Tetanus Toxoid - immunology | Infants | Research | Vaccines | Microbiota (Symbiotic organisms) | Health aspects | Polymerase chain reaction | Babies | Bacteria | Immunoglobulins | Lymphocytes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text A multistage tuberculosis vaccine that confers efficient protection before and after exposure
by Aagaard, Claus and Hoang, Truc and Dietrich, Jes and Cardona, Pere-Joan and Izzo, Angelo and Dolganov, Gregory and Schoolnik, Gary K and Cassidy, Joseph P and Billeskov, Rolf and Andersen, Peter
Nature Medicine, ISSN 1078-8956, 02/2011, Volume 17, Issue 2, pp. 189 - 195
All tuberculosis vaccines currently in clinical trials are designed as prophylactic vaccines based on early expressed antigens. We have developed a multistage... 
MYCOBACTERIUM-TUBERCULOSIS | MEDICINE, RESEARCH & EXPERIMENTAL | CD4 T-CELLS | BIOCHEMISTRY & MOLECULAR BIOLOGY | BCG | HIV EPIDEMIC | SUBUNIT VACCINE | CELL BIOLOGY | IMMUNE-RESPONSES | GENE-EXPRESSION | FUSION PROTEIN | GUINEA-PIG MODEL | ANTIGEN 85B | Latent Tuberculosis - prevention & control | Mice, Inbred C57BL | Mycobacterium tuberculosis - immunology | Tuberculosis, Pulmonary - drug therapy | Vaccines, Synthetic - therapeutic use | Interferon-gamma - metabolism | Tuberculosis, Pulmonary - prevention & control | Bacterial Proteins - therapeutic use | Gene Expression Regulation, Bacterial - physiology | Gene Expression Regulation, Bacterial - drug effects | Tuberculosis, Pulmonary - immunology | Animals | Latent Tuberculosis - drug therapy | Polymerase Chain Reaction | Mice | Antigens, Bacterial - therapeutic use | Tuberculosis Vaccines - immunology | Tuberculosis Vaccines - therapeutic use | Mycobacterium tuberculosis - metabolism | Disease Models, Animal | Physiological aspects | Antigens | Tuberculosis vaccines | Research | T cells | Health aspects | Tuberculosis | Biomedical research | Vaccines | Rodents | Immune system
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
by Alfred Witjes, J and Lebret, Thierry and Compérat, Eva M and Cowan, Nigel C and De Santis, Maria and Bruins, Harman Maxim and Hernández, Virginia and Espinós, Estefania Linares and Dunn, James and Rouanne, Mathieu and Neuzillet, Yann and Veskimäe, Erik and van der Heijden, Antoine G and Gakis, Georgios and Ribal, Maria J
European Urology, ISSN 0302-2838, 2016, Volume 71, Issue 3, pp. 462 - 475
Abstract Context Invasive bladder cancer is a frequently occurring disease with a high mortality rate despite optimal treatment. The European Association of... 
Urology | Cystectomy | Treatment | Multimodality | EAU | Metastatic | Muscle invasive | Diagnosis | Bladder cancer | Follow-up | Guidelines | LYMPH-NODE DISSECTION | BACILLUS-CALMETTE-GUERIN | UROTHELIAL CARCINOMA | INTENSITY-MODULATED RADIOTHERAPY | PHASE-III TRIAL | URINARY-DIVERSION | TRANSITIONAL-CELL CARCINOMA | RADICAL CYSTECTOMY | UROLOGY & NEPHROLOGY | QUALITY-OF-LIFE | RECURRENCE-FREE SURVIVAL | Neoplasm Invasiveness | Europe | Humans | Carcinoma, Transitional Cell - secondary | Cystoscopy | Carcinoma, Transitional Cell - therapy | Urinary Bladder - pathology | Radiotherapy | Neoplasm Metastasis | Societies, Medical | Carcinoma, Transitional Cell - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Urinary Bladder Neoplasms - therapy | Urinary Bladder Neoplasms - pathology | BCG Vaccine - therapeutic use | Adjuvants, Immunologic - therapeutic use | Muscle, Smooth - pathology | Mortality | Metastasis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Contrasting female-male mortality ratios after routine vaccinations with pentavalent vaccine versus measles and yellow fever vaccine. A cohort study from urban Guinea-Bissau
by Fisker, Ane B and Biering-Sørensen, Sofie and Lund, Najaaraq and Djana, Queba and Rodrigues, Amabelia and Martins, Cesario L and Benn, Christine S
Vaccine, ISSN 0264-410X, 2016, Volume 34, Issue 38, pp. 4551 - 4557
Highlights • Vaccines have sex-differential non-specific effects affecting mortality. • The transition from DTP to measles vaccine lowers female/male mortality... 
Allergy and Immunology | Non-specific/heterologous effects of vaccines | Sex-difference | Measles vaccine | Pentavalent vaccine | Mortality | SURVIVAL | MEDICINE, RESEARCH & EXPERIMENTAL | CHILDHOOD MORTALITY | DTP VACCINATION | BCG | RANDOMIZED-TRIAL | IMMUNOLOGY | BIRTH-WEIGHT CHILDREN | DOSE VITAMIN-A | DIPHTHERIA-TETANUS-PERTUSSIS | WEST-AFRICAN | AGE | Haemophilus Vaccines - therapeutic use | Guinea-Bissau - epidemiology | Measles Vaccine - therapeutic use | Yellow Fever Vaccine - adverse effects | Haemophilus Vaccines - adverse effects | Yellow Fever Vaccine - therapeutic use | Humans | Proportional Hazards Models | Child, Preschool | Infant | Male | Random Allocation | Child Mortality | Measles Vaccine - adverse effects | Sex Ratio | Hepatitis B Vaccines - therapeutic use | Hepatitis B Vaccines - adverse effects | Immunization Programs | Sex Factors | Survival Analysis | Female | Diphtheria-Tetanus-Pertussis Vaccine - therapeutic use | Child | Diphtheria-Tetanus-Pertussis Vaccine - adverse effects | Medical research | Analysis | Measles | Vaccination | Medicine, Experimental | Health aspects | Influenza vaccines | Whooping-cough | Influenza | Tetanus | Low income groups | Immunization | Vaccines | Fever | Children & youth | Vitamin A | Survival analysis | Ratios | Hypotheses | Birth weight | Age
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults
by Abel, Brian and Tameris, Michele and Mansoor, Nazma and Gelderbloem, Sebastian and Hughes, Jane and Abrahams, Deborah and Makhethe, Lebohang and Erasmus, Mzwandile and de Kock, Marwou and van der Merwe, Linda and Hawkridge, Anthony and Veldsman, Ashley and Hatherill, Mark and Schirru, Giulia and Pau, Maria Grazia and Heniks, Jenny and Weverling, Gerrit Jan and Goudsmit, Jaap and Sizemore, Donata and McClain, J. Bruce and Goetz, Margaret and Gearhart, Jacqueline and Mahomed, Hassan and Hussey, Gregory D and Sadoff, Jerald C and Hanekom, Willem A
American journal of respiratory and critical care medicine, ISSN 1073-449X, 2010, Volume 181, Issue 12, pp. 1407 - 1417
RATIONALE: AERAS-402 is a novel tuberculosis vaccine designed to boost immunity primed by bacillus Calmette-Guérin (BCG), the only licensed vaccine.... 
CD4 | Vaccine | Tuberculosis | Immunity | CD8 | MYCOBACTERIUM-TUBERCULOSIS | IFN-GAMMA | tuberculosis | ANTI-AD5 IMMUNITY | immunity | MALARIA VACCINE | vaccine | TUMOR-NECROSIS-FACTOR | HEALTHY-ADULTS | IMMUNOGENICITY | PREEXISTING IMMUNITY | RESPIRATORY SYSTEM | IMMUNE-RESPONSES | BCG VACCINATION | CRITICAL CARE MEDICINE | Double-Blind Method | Follow-Up Studies | Humans | Male | CD4-Positive T-Lymphocytes - immunology | Dose-Response Relationship, Drug | Young Adult | Lymphocyte Activation - immunology | CD8-Positive T-Lymphocytes - drug effects | Adult | Female | South Africa | Tuberculosis Vaccines - immunology | Tuberculosis Vaccines - therapeutic use | CD8-Positive T-Lymphocytes - immunology | CD4-Positive T-Lymphocytes - drug effects | H. Tuberculosis and Mycobacterial Disease
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Status of vaccine research and development of vaccines for tuberculosis
by Evans, Thomas G and Schrager, Lew and Thole, Jelle
Vaccine, ISSN 0264-410X, 2016, Volume 34, Issue 26, pp. 2911 - 2914
Highlights • Tuberculosis is now the leading infectious disease cause of death in the world. • There are more than 10 clinical candidates in various phases of... 
Allergy and Immunology | Vaccine | Tuberculosis | BCG | Latency | MYCOBACTERIUM-TUBERCULOSIS | MEDICINE, RESEARCH & EXPERIMENTAL | METAANALYSIS | IMMUNOLOGY | Mass Vaccination | Animals | Mycobacterium tuberculosis | Humans | Tuberculosis - prevention & control | Biomedical Research - trends | Clinical Trials as Topic | BCG Vaccine - therapeutic use | Tuberculosis Vaccines - therapeutic use | Medicine, Experimental | Medical research | Tuberculosis vaccines | Industrial research | Vaccination | Drug resistance in microorganisms | Disease transmission | Analysis | Communicable diseases | Development and progression | Infants | Antigens | Global health | Candidates | Young adults | Research & development--R&D | Funding | Mortality | Clinical trials | Infections | Vaccines | Drug resistance | Prevention | Proteins | Adenoviruses | Influenza | Teenagers | Portfolio management | Immune system
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Making wider use of the world's most widely used vaccine: Bacille Calmette-Guérin revaccination reconsidered
by Dye, Christopher
Journal of the Royal Society Interface, ISSN 1742-5689, 10/2013, Volume 10, Issue 87, pp. 20130365 - 20130365
Approximately 100 million newborn children receive Bacille Calmette-Guerin (BCG) annually, because vaccination is consistently protective against childhood... 
Bacille Calmette-Guérin | Immunization | Revaccination | Tuberculosis | Adolescents | Cost-effectiveness | MYCOBACTERIUM-TUBERCULOSIS | cost-effectiveness | SOUTH-AFRICA | MAXIMUM-LIKELIHOOD | adolescents | MULTIDISCIPLINARY SCIENCES | tuberculosis | Bacille Calmette-Guerin | TUBERCULOSIS INFECTION | ANNUAL RISK | ACTIVE TUBERCULOSIS | immunization | revaccination | BCG VACCINATION | HIGH HIV | CLUSTER-RANDOMIZED TRIAL | Models, Theoretical | Immunization, Secondary | Cost-Benefit Analysis | Humans | Tuberculosis - prevention & control | Adolescent | Immunization Programs - economics | South Africa | BCG Vaccine - therapeutic use | Tuberculosis - transmission | 1004 | Bacille Calmette–Guérin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Bacillus Calmette–Guerin (BCG) immunotherapy for bladder cancer: Current understanding and perspectives on engineered BCG vaccine
by Kawai, Koji and Miyazaki, Jun and Joraku, Akira and Nishiyama, Hiroyuki and Akaza, Hideyuki
Cancer Science, ISSN 1347-9032, 01/2013, Volume 104, Issue 1, pp. 22 - 27
Since the first report in 1976, accumulated clinical evidence has supported intravesical B acillus C almette– G uerin ( BCG ) therapy as one of the standard... 
IMMUNE-RESPONSE | NANO DEVICE | GENE DELIVERY | ONCOLOGY | INTRAVESICAL THERAPY | URINARY INTERLEUKIN-8 | TUMOR-CELLS | MEDIATED ANTITUMOR-ACTIVITY | DELTA-T-CELLS | MAINTENANCE THERAPY | CARCINOMA IN-SITU | Mycobacterium bovis - immunology | Humans | Vaccines, Synthetic - therapeutic use | Vaccines, Synthetic - immunology | Urothelium - pathology | Immunotherapy - adverse effects | Vaccines, Synthetic - adverse effects | BCG Vaccine - adverse effects | Urinary Bladder Neoplasms - therapy | BCG Vaccine - immunology | Urinary Bladder Neoplasms - immunology | Administration, Intravesical | BCG Vaccine - therapeutic use | Liposomes | Urothelium - microbiology | Cancer vaccines | Care and treatment | Drug therapy | Bladder cancer | Immunotherapy | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG
by Brausi, Maurizio and Oddens, Jorg and Sylvester, Richard and Bono, Aldo and van de Beek, Cees and van Andel, George and Gontero, Paolo and Turkeri, Levent and Marreaud, Sandrine and Collette, Sandra and Oosterlinck, Willem
European Urology, ISSN 0302-2838, 01/2014, Volume 65, Issue 1, pp. 69 - 76
Although bacillus Calmette-Guérin (BCG) has proven highly effective in non–muscle-invasive bladder cancer (NMIBC), but it can cause severe local and systemic... 
Non–muscle-invasive bladder cancer | Maintenance BCG | Side effects | Urothelial carcinoma | Dose reduction | Non-muscle-invasive bladder cancer | MITOMYCIN-C | EUROPEAN ORGANIZATION | FORMAL METAANALYSIS | TOXICITY | TUMORS | 27 MG | UROLOGY & NEPHROLOGY | PRACTICE RECOMMENDATIONS | III TRIAL | PROGRESSION | Risk Assessment | Time Factors | BCG Vaccine - adverse effects | Humans | Urinary Bladder Neoplasms - pathology | Carcinoma, Papillary - drug therapy | BCG Vaccine - therapeutic use | Urinary Bladder Neoplasms - drug therapy | Neoplasm Staging | Carcinoma, Papillary - pathology | BCG Vaccine - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets
by Pietzak, Eugene J and Bagrodia, Aditya and Cha, Eugene K and Drill, Esther N and Iyer, Gopa and Isharwal, Sumit and Ostrovnaya, Irina and Baez, Priscilla and Li, Qiang and Berger, Michael F and Zehir, Ahmet and Schultz, Nikolaus and Rosenberg, Jonathan E and Bajorin, Dean F and Dalbagni, Guido and Al-Ahmadie, Hikmat and Solit, David B and Bochner, Bernard H
European Urology, ISSN 0302-2838, 2017, Volume 72, Issue 6, pp. 952 - 959
Abstract Background Molecular characterization of nonmuscle invasive bladder cancer (NMIBC) may provide a biologic rationale for treatment response and novel... 
Urology | Bacillus Calmette-Guérin | DNA damage repair | Nonmuscle invasive bladder cancer | Targeted therapy | Genomics | Immunotherapy | AT-Rich interaction domain 1A | SURVIVAL | UROTHELIAL CARCINOMA | INACTIVATION | Bacillus Calmette-Guerin | ANEUPLOIDY | STAG2 | HIGH-RISK | URINE | UROLOGY & NEPHROLOGY | GRADE | MUTATIONS | PROMOTER | Class I Phosphatidylinositol 3-Kinases - genetics | Receptor, ErbB-2 - genetics | Exons | Humans | Middle Aged | Male | DNA Repair - genetics | Molecular Targeted Therapy | Histone Demethylases - genetics | Tumor Suppressor Protein p53 - genetics | DNA Copy Number Variations | Neoplasm Grading | Telomerase - genetics | Urinary Bladder Neoplasms - genetics | Urinary Bladder Neoplasms - pathology | Aged, 80 and over | DNA Damage - genetics | Adult | Female | Nuclear Proteins - genetics | Receptor, Fibroblast Growth Factor, Type 3 - genetics | Neoplasm Invasiveness | Kaplan-Meier Estimate | Proportional Hazards Models | Gene Fusion | Transcription Factors - genetics | Cystectomy | Antigens, Nuclear - genetics | Antineoplastic Agents, Immunological - therapeutic use | Urinary Bladder Neoplasms - therapy | Biomarkers | Neoplasm Recurrence, Local - genetics | Aged | High-Throughput Nucleotide Sequencing | BCG Vaccine - therapeutic use | Mutation | Neoplasm Staging | Bladder cancer | Health aspects | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Vaccine against tuberculosis: what's new?
by Montagnani, Carlotta and Montagnani, Carlotta and Chiappini, Elena and Chiappini, Elena and Galli, Luisa and Galli, Luisa and de Martino, Maurizio and de Martino, Maurizio
BMC infectious diseases, ISSN 1471-2334, 2014, Volume 14, Issue Suppl 1, pp. S2 - S2
Background: one of the World Health Organization Millennium Development Goal is to reduce tuberculosis incidence by 2015. However, more of 8.5 million... 
MYCOBACTERIUM-TUBERCULOSIS | EFFICIENT PROTECTION | INFECTIOUS DISEASES | BACILLUS-CALMETTE-GUERIN | LATENT TUBERCULOSIS | BCG VACCINE | CANDIDATE TB VACCINE | HIV-INFECTED ADULTS | POLYFUNCTIONAL CD4(+) | SUBUNIT VACCINE | RECOMBINANT ADENOVIRUS | Tuberculosis - epidemiology | Tuberculosis - immunology | Immunization, Secondary | Adjuvants, Immunologic | Humans | Tuberculosis - prevention & control | BCG Vaccine - immunology | Tuberculosis Vaccines - immunology | Tuberculosis Vaccines - therapeutic use | Pediatrics | Health sciences | Tuberculosis | Disease | Cytokines | Human immunodeficiency virus--HIV | Colleges & universities | Clinical trials | Interferon | Vaccines | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Preventive vaccines for tuberculosis
by Evans, Thomas G and Brennan, Michael J and Barker, Lew and Thole, Jelle
Vaccine, ISSN 0264-410X, 2012, Volume 31, Issue 2, pp. B223 - B226
Highlights ► Over 16 TB vaccine candidates have entered into human clinical trials. ► A clear correlate of protection of TB vaccination is not yet known. ► The... 
Allergy and Immunology | Vaccine | Tuberculosis | Correlates | BCG | MYCOBACTERIUM-TUBERCULOSIS | MEDICINE, RESEARCH & EXPERIMENTAL | BACILLE-CALMETTE-GUERIN | IMMUNITY | METAANALYSIS | SAFETY | ADULTS | IMMUNOLOGY | PROTECTIVE EFFICACY |